Cargando…
SGK1 in Cancer: Biomarker and Drug Target
Serum- and glucocorticoid-regulated kinases (SGKs) are members of the AGC family of serine/threonine kinases, consisting of three isoforms: SGK1, SGK2, and SGK3. SGK1 was initially cloned as a gene transcriptionally stimulated by serum and glucocorticoids in rat mammary tumor cells. It is upregulate...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139822/ https://www.ncbi.nlm.nih.gov/pubmed/35625991 http://dx.doi.org/10.3390/cancers14102385 |
_version_ | 1784714949642158080 |
---|---|
author | Cicenas, Jonas Meskinyte-Kausiliene, Edita Jukna, Vigilijus Rimkus, Arnas Simkus, Jokubas Soderholm, Diana |
author_facet | Cicenas, Jonas Meskinyte-Kausiliene, Edita Jukna, Vigilijus Rimkus, Arnas Simkus, Jokubas Soderholm, Diana |
author_sort | Cicenas, Jonas |
collection | PubMed |
description | Serum- and glucocorticoid-regulated kinases (SGKs) are members of the AGC family of serine/threonine kinases, consisting of three isoforms: SGK1, SGK2, and SGK3. SGK1 was initially cloned as a gene transcriptionally stimulated by serum and glucocorticoids in rat mammary tumor cells. It is upregulated in some cancers and downregulated in others. SGK1 increases tumor cell survival, adhesiveness, invasiveness, motility, and epithelial to mesenchymal transition. It stimulates tumor growth by mechanisms such as activation of K(+) channels and Ca(2+) channels, Na(+)/H(+) exchanger, amino acid and glucose transporters, downregulation of Foxo3a and p53, and upregulation of β-catenin and NFκB. This chapter focuses on major aspects of SGK1 involvement in cancer, its use as biomarker as well as potential therapeutic target. |
format | Online Article Text |
id | pubmed-9139822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91398222022-05-28 SGK1 in Cancer: Biomarker and Drug Target Cicenas, Jonas Meskinyte-Kausiliene, Edita Jukna, Vigilijus Rimkus, Arnas Simkus, Jokubas Soderholm, Diana Cancers (Basel) Commentary Serum- and glucocorticoid-regulated kinases (SGKs) are members of the AGC family of serine/threonine kinases, consisting of three isoforms: SGK1, SGK2, and SGK3. SGK1 was initially cloned as a gene transcriptionally stimulated by serum and glucocorticoids in rat mammary tumor cells. It is upregulated in some cancers and downregulated in others. SGK1 increases tumor cell survival, adhesiveness, invasiveness, motility, and epithelial to mesenchymal transition. It stimulates tumor growth by mechanisms such as activation of K(+) channels and Ca(2+) channels, Na(+)/H(+) exchanger, amino acid and glucose transporters, downregulation of Foxo3a and p53, and upregulation of β-catenin and NFκB. This chapter focuses on major aspects of SGK1 involvement in cancer, its use as biomarker as well as potential therapeutic target. MDPI 2022-05-12 /pmc/articles/PMC9139822/ /pubmed/35625991 http://dx.doi.org/10.3390/cancers14102385 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Commentary Cicenas, Jonas Meskinyte-Kausiliene, Edita Jukna, Vigilijus Rimkus, Arnas Simkus, Jokubas Soderholm, Diana SGK1 in Cancer: Biomarker and Drug Target |
title | SGK1 in Cancer: Biomarker and Drug Target |
title_full | SGK1 in Cancer: Biomarker and Drug Target |
title_fullStr | SGK1 in Cancer: Biomarker and Drug Target |
title_full_unstemmed | SGK1 in Cancer: Biomarker and Drug Target |
title_short | SGK1 in Cancer: Biomarker and Drug Target |
title_sort | sgk1 in cancer: biomarker and drug target |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139822/ https://www.ncbi.nlm.nih.gov/pubmed/35625991 http://dx.doi.org/10.3390/cancers14102385 |
work_keys_str_mv | AT cicenasjonas sgk1incancerbiomarkeranddrugtarget AT meskinytekausilieneedita sgk1incancerbiomarkeranddrugtarget AT juknavigilijus sgk1incancerbiomarkeranddrugtarget AT rimkusarnas sgk1incancerbiomarkeranddrugtarget AT simkusjokubas sgk1incancerbiomarkeranddrugtarget AT soderholmdiana sgk1incancerbiomarkeranddrugtarget |